Introduction {#s1}
============

*Enterobacteriaceae* manifest resistance to third-generation cephalosporins by the production of extended-spectrum β-lactamases (ESBLs), chromosomal AmpC (cAmpCs), or plasmid-mediated AmpCs (pAmpCs) (Jacoby, [@B15]). However, AmpCs do not hydrolyze fourth-generation cephalosporins, such as cefepime (FEP) (Jacoby, [@B15]). Therefore, FEP is suggested for the treatment of infections caused by AmpC producers. Plasmid-mediated extended-spectrum AmpC β-lactamases (pESACs) with mutations in AmpC that enhance catalytic activity toward cefepime, derived from the most frequently detected pAmpC, *bla*~CMY−2~, have been identified (Nordmann and Mammeri, [@B28]; Doi et al., [@B10]; Jacoby, [@B15]). Doi et al. showed a reduced susceptibility to FEP among *Escherichia coli* clinical isolates producing novel variants of *bla*~CMY−2~, *bla*~CMY−33~, and *bla*~CMY−44~ (Doi et al., [@B10]). However, for these pESACs, structural information regarding their hydrolytic performance on different β-lactam antibiotics is yet to be characterized.

Among the β-lactams currently available, carbapenems are unique because they are relatively resistant to hydrolysis by most β-lactamases (Barry et al., [@B4]). Carbapenems have thus been considered as the last resort of drugs for treating infections caused by multi-drug resistant Gram-negative bacilli. Carbapenem resistance in *Enterobacteriaceae* can arise by several mechanisms, including mutations that alter the expression and/or function of porins, or overexpression of active efflux pumps, while the greatest concern has been placed on acquired transferable carbapenemases (Temkin et al., [@B37]). *bla*~OXA~-type (*bla*~OXA−48~ and *bla*~OXA−181~) or *bla*~NDM~ are the dominant carbapenemases found in *E. coli* (Nordmann et al., [@B29]; Temkin et al., [@B37]; Al-Agamy et al., [@B2]). Overproduction of class C β-lactamases, such as *bla*~CMY−2~, or ESBL, can also lead to carbapenem resistance in *E. coli*, when combined with impermeability caused by porin (OmpC or OmpF) loss (Ma et al., [@B26]). Moreover, Dupont et al. reported that a Gly-63-Val substitution in OmpR, which codes for a regulatory protein involved in the control of OmpC/OmpF porin expression, caused the ertapenem resistance in *E. coli* (Dupont et al., [@B11]).

During evolution, the ability of bacteria to adapt to various hosts and environments has been favored by the acquisition of DNA elements through horizontal gene transfer or spontaneous mutations (Frost et al., [@B12]; Ilyas et al., [@B14]). The accumulation of antibiotic resistance, loss of nonessential genes, metabolic alterations, and virulence factor attenuation all occur when pathogenic organisms adapt to the host (Viberg et al., [@B38]). Antibiotic exposures also facilitate the genomic evolution of antibiotic resistance-associated genes (Pires et al., [@B31]; Lin et al., [@B24]). Here, we report a clinical case that illustrates the dynamic nature of an IncI1 plasmid within the host, as *bla*~CMY−111~ was changed to *bla*~CMY−4~ in *E. coli*.

Materials and methods {#s2}
=====================

Bacterial strains and culture conditions
----------------------------------------

The bacterial strains and plasmids used in this study are described in Table [1](#T1){ref-type="table"}. On day 1, an *E. coli* isolate (EC974) isolated from a 76-year-old women with urinary tract infection (UTI) showed intermediate resistance to piperacillin/tazobactam (TZP) but was susceptible to cefpirome (CPO), cefepime (FEP), and ertapenem (ETP). Once admitted, she was empirically started on ceftriaxone (CRO). After a week, the therapy was switched to cefixime (CFM) and continued for 4 days. One hundred and six days later, the woman was hospitalized due to recurrent UTI and was treated with imipenem (IMP). Two days later, an *E. coli* strain (EC1515) showing resistance to TZP, CPO, FEP, and ETP was isolated. *E. coli* was grown on Luria-Bertani (LB) agar or in broth. Bacteria harboring antibiotic resistance determinants were grown in the presence of the appropriate antibiotics at the following concentrations: ampicillin (AMP, 100 μg/mL); rifampicin (RIF, 256 μg/mL). All strains were stored at −80°C in LB broth containing 20% glycerol until testing.

###### 

Strains and plasmids used in this study.

  **Strain or plasmid**     **Relevant genotype or description**                               **Reference or source**
  ------------------------- ------------------------------------------------------------------ -------------------------
  **STRAIN**                                                                                   
  EC974                     TZP^I^, FEP^S^, CPO^S^, ETP^S^                                     This study
  EC1515                    TZP^R^, FEP^SDD^, CPO^R^, ETP^R^                                   This study
  C600                      RIF^R^, recipient for conjugation assay                            Laboratory stock
  EC974-TCG                 C600 transconjugant contains plasmids, pEC974-1 and pEC974-3       This study
  EC1515-TCG                C600 transconjugant contains plasmids, pEC1515-1 and pEC1515-3     This study
  DH5α                      F^−^Ψ *80dlacZΔM15 Δ(lacZYA-argF) U169 hsdR17 recA1 thi-1 relA1*   Laboratory stock
  DH5α-*bla*~CMY−111~       DH5α contains pACYC177-*bla*~CMY−111~                              This study
  DH5α-*bla*~CMY−4~         DH5α contains pACYC177-*bla*~CMY−4~                                This study
  **PLASMID**                                                                                  
  pACYC177                  A general cloning vector; AMP^R^                                   Invitrogen
  pACYC177-*bla*~CMY−111~   pACYC177 contains the *bla*~CMY−111~; AMP^R^                       This study
  pACYC177-*bla*~CMY−4~     pACYC177 contains the *bla*~CMY−4~; AMP^R^                         This study

*AMP, ampicillin; CPO, cefpirome; ETP, ertapenem; FEP, cefepime; RIF, rifampicin; TZP, piperacillin/tazobactam*.

*S, sensitive; SDD, susceptible-dose dependent; I, intermediate resistance; R, resistant*.

Antibiotic susceptibility testing
---------------------------------

Antibiotic susceptibility of the strains was determined by the disk diffusion method on Mueller-Hinton (MH) agar, based on the CLSI guidelines (Clinical and Laboratory Standards Institute, [@B8]). Susceptibility to AMP, amoxicillin (AMC), amikacin (AN), chloramphenicol (CAP), ceftazidime (CAZ), CFM, ciprofloxacin (CIP), cefmetazole (CMZ), cefpodoxime (CPD), CPO, CRO, cefuroxime (CXM), cefazolin (CZ), ETP, FEP, gentamycin (GN), IPM, lomefloxacin (LOM), levofloxacin (LVX), meropenem (MEM), tobramycin (NN), cotrimoxazole (SXT), tetracycline (TE), and TZP was done. *E. coli* ATCC 25922 and *Klebsiella pneumoniae* ATCC 700603 were used as quality control strains. The interpretation of susceptibility to these antibiotics was determined according to the recommendations of the Clinical and Laboratory Standards Institute ([@B9]).

Genome sequencing, assembly, annotation, and analysis
-----------------------------------------------------

Genomic DNA for *E. coli* EC974 and EC1515 was prepared using the Qiagen DNeasy Blood and Tissue kit (California, USA), according to the manufacturer\'s instructions. The genomes of EC974 and EC1515 were sequenced using the PacBio RS II platform (Pacific Biosciences, USA). HGAP3 in the SMRT analysis (v2.3) was used to assemble the PacBio data with default parameters, except the genome size was set as 5.5 Mb (Kao et al., [@B18]). HGAP3 analysis gave seven contigs for both strains. Contigs with a low coverage (\< 20% of the mean) and/or shorter than 20 kb were discarded. This resulted in five and four contigs for the strains EC974 and EC1515, respectively. The remaining shortest contig of the strain EC974 was found highly similar to segments of another larger contig and there was a sudden drop in read coverage, so that contig was discarded. We therefore reported one chromosome and three plasmids for both strains.

For each contig, we aligned the first and last 20,000 bp using BLAT (v35, option: minMatch = 1) (Kent, [@B19]). Nearly perfect matches of lengths 4.6--16.6 kb were found for all contigs, suggesting their circular nature. We noted that the first 520 bp of the second largest contig of strain EC974 did not align well to the tail of the contig. The perfect match of \~4 kb which followed suggested false assembly at the contig start. Therefore, the first 520 bp of the contig was trimmed. A similar observation was made for the second largest contig of strain EC1515, and the first 554 bp was trimmed.

To circularize the contigs, we trimmed redundant segments at both contig ends. Specifically, the mid-point of the nearly perfect match was determined and bases from either end to the mid-point were trimmed. In addition, we adjusted contig orientation and starting position to match those of a reference sequence. For each contig, a closest reference was found via alignment against the NCBI NR database using BLAST. For both strains, the closest references (i.e., with the largest query coverage) of the four contigs from large to small were the chromosome of *E. coli* strain O157:H16, *Salmonella* enterica strain BL10 plasmid (CP025339), *E. coli* strain EHS30-1 plasmid (KX772391), and *E. coli* plasmid pH1038-142 (KJ484634), respectively. Instead of using the chromosome of *E. coli* strain O157:H16 as reference, we used the strain O157:H7 as reference because it is one of the official reference genomes of *E. coli*. Note that for the smallest contig of each strain, we fixed the starting position as the 61370th base of the plasmid pH1038-142 because the first base of that plasmid was not detected in our contig.

Sequences were annotated at the RAST prokaryotic genome annotation server (<http://rast.nmpdr.org/>) (Aziz et al., [@B3]). Microbial genome BLAST was used for the genome sequence similarity searching of the *E. coli* complete genome database (<https://blast.ncbi.nlm.nih.gov/Blast.cgi?PAGE_TYPE=BlastSearch&BLAST_SPEC=MicrobialGenomes>). The multilocus sequence typing (MLST), ResFinder, and PlasmidFinder databases (<http://www.genomicepidemiology.org/>) were used to find the sequence type (ST), serotype, antibiotic resistance genes, and the plasmid types present in the isolates EC974 and EC1515 (Larsen et al., [@B22]; Zankari et al., [@B41]). Insertion sequences (ISs) were characterized using the IS Finder database (<https://www-is.biotoul.fr/>).

Comparative genome analysis
---------------------------

We used the command dnadiff of MUMMER (v3.23, default parameters) (Pop et al., [@B32]) to compare genomes of the two *E. coli* strains. Qualities of assemblies at the loci of SNPs and small INDELs were examined and those with a quality ≥ 30 within the homopolymer stretch were further analyzed.

Nucleotide sequence accession numbers
-------------------------------------

The complete genome sequences of the *E. coli* strains EC974 and EC1515 have been deposited in GenBank under the accession numbers [CP021840](CP021840) (EC974 chromosome), [CP021841](CP021841) (pEC974-1), [CP021842](CP021842) (pEC974-2), [CP021843](CP021843) (pEC974-3), [CP021844](CP021844) (EC1515 chromosome), [CP021845](CP021845) (pEC1515-1), [CP021846](CP021846) (pEC1515-2), and [CP021847](CP021847) (pEC1515-3).

Conjugation experiments and plasmid analysis
--------------------------------------------

The liquid mating-out assay was used to transfer *bla*~CMY~ genes from parental isolates (EC974 or EC1515) to RIF-resistant *E. coli* C600 as described previously (Kao et al., [@B17]). Transconjugants were selected on LB plates containing RIF (256 μg/mL) and CTX (2 μg/mL). Plasmid numbers in the parental strains and transconjugants were determined as described previously (Kado and Liu, [@B16]).

Cloning of *bla*~CMY~ genes
---------------------------

*bla*~CMY−4~ and *bla*~CMY−111~ were cloned into pACYC177 and transformed into *E. coli* DH5α cells. In brief, the 2,184 bp *bla*~CMY~ fragment (contained a promoter region) obtained from EC974 and EC1515 plasmid DNA and PCR with primers *bla*~CMY−1~ (5′-TTGCCGGCCGGTGGGTCATCTCTTGCTA-3′) and *bla*~CMY−2~ (5′-TTGCCGGCCGGTCGAGTGCAATTACGTT-3′), was digested by *Nae*I and ligated to the plasmid pACYC177 (digested by *Psi*I) to generate plasmids pACYC177-*bla*~CMY−111~ and pACYC177-*bla*~CMY−4~, respectively, and then transformed into DH5α cells. Antibiotics CTX (2 μg/mL) combined with AMP (100 μg/mL) were used to select for the *bla*~CMY−4~ or *bla*~CMY−111~ producers.

Results {#s3}
=======

Antibiotic susceptibility and clonal relationship of EC974 and EC1515
---------------------------------------------------------------------

After CRO, CFM, and IMP treatments, EC1515 was isolated from a patient with recurrent UTI infection. Compared to EC974 from the same patient, EC1515 was more resistant to TZP, FEP, CPO, and ETP, than EC974 (Table [2](#T2){ref-type="table"}), and had a rough colony morphology (Figure [S1](#SM1){ref-type="supplementary-material"}). To investigate whether the patient was recurrently infected by the same *E. coli* clone, the clonal relationships between the two isolates were analyzed by RAPD-PCR with primer 1254 (Pacheco et al., [@B30]). The results showed highly polymorphic profiles, distinguishing individual *E. coli* isolates (Figure [S2](#SM1){ref-type="supplementary-material"}). EC974 and EC1515 showing identical RAPD-PCR profiles were considered to be the same clone (Figure [S2](#SM1){ref-type="supplementary-material"}).

###### 

Antibiotic susceptibility of *E. coli* isolates EC974 and EC1515.

  **Isolate**   **Date**   **Antibiotic susceptibility**                                                                                             
  ------------- ---------- ------------------------------- --- --- --- --- --- --- --- --- --- ----- --- --- --- --- --- --- --- --- --- --- --- --- ---
  EC974         960824     R                               R   I   R   R   R   R   R   R   R   S     S   S   S   S   S   I   R   S   S   S   R   R   R
  EC1515        961210     R                               R   R   R   R   R   R   R   R   R   SDD   R   S   R   S   S   I   R   S   S   S   R   R   R

*Antibiotic susceptibility tests were performed in duplicate*.

*AMP, ampicillin; AMC, amoxicillin; TZP, piperacillin/tazobactam; CZ, cefazolin; CXM, cefuroxime; CMZ, cefmetazole; CAZ, ceftazidime; CRO, ceftriaxone; CPD, cefpodoxime; CFM, cefixime; FEP, cefepime; CPO, cefpirome; IPM, imipenem; ETP, ertapenem; MEM, meropenem; LVX, levofloxacin; CIP, ciprofloxacin; LOM, lomefloxacin; GN, gentamycin; NN, tobramycin; AN, amikacin; TE, tetracycline; CAP, chloramphenicol; SXT, cotrimoxazole*.

*S, sensitive; SDD, susceptible-dose dependent; I, intermediate resistance; R, resistant*.

Complete genome sequences of EC974 and EC1515 and their characteristics
-----------------------------------------------------------------------

For the two *E. coli* strains EC974 and EC1515, PacBio sequencing generated 106,134 and 106,265 polymerase reads, and the total numbers of bases were 1,475,613,460 and 1,581,950,763, respectively. The N50 lengths of the 159,569 and 177,682 subreads were 12,365 and 12,090 bp, respectively. For each strain, the data was assembled using HGAP3 and the resulting contigs were circularized. Mean read coverage across the genome were 147X and 198X, respectively for strains EC974 and EC1515. We reported one chromosome and three plasmids for both strains and their lengths were shown in Table [3](#T3){ref-type="table"}. The results showed that the EC974 and EC1515 genomes had a size of 5,168,339 and 5,167,364 bp, respectively (Table [3](#T3){ref-type="table"}). The GC contents of the two strains were both 50.24% (Table [3](#T3){ref-type="table"}). RAST annotation results showed that the EC974 genome contained 4,906 coding sequences and 112 RNA genes, and the EC1515 genome contained 4,911 coding sequences and 112 RNA genes (Table [3](#T3){ref-type="table"}). Moreover, 61% of the protein coding sequences were functionally annotated by the RAST server into 610 and 609 subsystems in EC974 and EC1515 strains, respectively.

###### 

Characteristics of chromosomes and plasmids in isolates EC974 and EC1515.

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Characteristics**                                                                                                                                                                              
  --------------------- --------------- --------------------- ----------------------- ------------------------------- ---------------------------------------------------------------------------- -------------------------------------------
  **CHROMOSOMES**                                                                                                                                                                                  

                        **Size (bp)**   **GC contents (%)**   **ORF (*****n*****)**   **RNA (*****n*****)**           **Antimicrobial resistance genes**                                           

  EC974                 5,168,339       50.24                 4906                    112                             *bla*~TEM−1~, *cmlA1, sul3, tetM, mefB, aadA1*                               

  EC1515                5,167,364       50.24                 4911                    112                             *bla*~TEM−1~, *cmlA1, sul3, tetM, mefB, aadA1*                               

  **PLASMIDS**                                                                                                                                                                                     

                        **Size (bp)**   **Replicon**          **ORF**                 **Conjugative related genes**   **High similarity plasmid (gene bank accession)**                            **Antimicrobial resistance genes**

  EC974                                                                                                                                                                                            

      pEC974-1          105,321         IncI1                 123                     \+                              *Escherichia coli* strain TVGHEC01\                                          *aadA22, aac(3)-IId, bla*~CMY−111~
                                                                                                                      plasmid ([LC019731](LC019731))                                               

      pEC974-2          92,404          P0111                 105                     --                              *Escherichia coli* strain EHS30-1, plasmid pEHS30-1 ([KX772391](KX772391))   *aadA2, tetA, dfrA12*

      pEC974-3          78,518          IncFII                94                      \+                              *Escherichia coli* strain V423\                                              *bla*~TEM−1~, *aadA1, aadA22, sul3, inuF*
                                                                                                                      plasmid pV423-b ([LC056646](LC056646))                                       

  EC1515                                                                                                                                                                                           

      pEC1515-1         105,492         IncI1                 123                     \+                              *Escherichia coli* strain TVGHEC01\                                          *aadA22, aac(3)-IId, bla*~CMY−4~
                                                                                                                      plasmid ([LC019731](LC019731))                                               

      pEC1515-2         92,352          P0111                 102                     \-                              *Escherichia coli* strain EHS30-1, plasmid pEHS30-1 ([KX772391](KX772391))   *aadA2, tetA, dfrA12*

      pEC1515-3         78,518          IncFII                92                      \+                              *Escherichia coli* strain V423\                                              *bla*~TEM−1~, *aadA1, aadA22, sul3, inuF*
                                                                                                                      plasmid pV423-b ([LC056646](LC056646))                                       
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Serotype was determined by the genotype of *fliC, wzx*, and *wzy*, and the results showed that both strains belonged to the O51-H34 serotype. Antimicrobial resistance genes against β-lactams (*bla*~TEM−1~), phenicol (*cmlA1*), sulphonamide (*sul3*), tetracycline (*tetM*), macrolide (*mefB*) and aminoglycoside (*aadA1*) were identified on both chromosome sequences (Table [3](#T3){ref-type="table"}). The MLST scheme of both isolates based on the sequences of seven housekeeping genes (*gyrB53, recA42, mdh24, purA1, icd58, adk58, fumC53*) confirmed that both isolates belonged to the ST219 type. Microbial genome BLAST results showed that the genome sequence of EC974 was highly similar to EC1515 (coverage 100%, identity 99%), DSM 103246 (coverage 92%, identity 99%, ST773), Santai (coverage 90%, identity 99%, ST773), RM12579 (coverage 90%, identity 99%, ST553), 2013C-4465 (coverage 90%, identity 99%, ST553), and CB9615 (coverage 90%, identity 99%, ST553), among 1,593 *E. coli* genomes in the database.

We further compared the genomes of the two strains using MUMMER and showed the 1-to-1 alignments allowing rearrangements in Table [4](#T4){ref-type="table"}. The results revealed that only two large-scale rearrangements on the chromosome: one 973 bp deletion (Chromosome: 941793-942765 of strain EC974) and one 1,881 bp inversion (Chromosome: 3045861-3047678 of strain EC974) on the chromosome. For the largest plasmid, we observed one 532 bp insertion (pEC1515-1: 17188-17719 of strain EC1515) and one 326 bp deletion (pEC974-1: 17647-17973 of strain EC974). No large-scale rearrangement was observed on the other two plasmids. The shortest plasmids of the two strains were perfectly identical. MUMMER also revealed 12 SNPs and 35 small INDELs. Of the 12 SNPs, 9 and 3 resided in the chromosome and plasmid 1, respectively (Table [5](#T5){ref-type="table"} and Table [S1](#SM1){ref-type="supplementary-material"}). Among the 12 SNPs, eight were missense mutations and the rest were either intergenic (three) or synonymous (one) (Table [5](#T5){ref-type="table"}). A majority of small INDELs were likely false due to the error-prone nature of PacBio data. Consistently, we found that many small INDELs occurred at loci of homopolymers and the assembly qualities were low. Of the 35 small INDELs, only 8 were of a high quality (quality ≥ 30) (Table [5](#T5){ref-type="table"}). Among the 8 high quality small INDELs, four resulted in a frame shift while the rest resided in intergenic regions (Table [5](#T5){ref-type="table"}). Taken together, these results showed the evolutionary relationships between EC974 and EC1515.

###### 

One-to-one alignments of the two genomes using MUMMER.

  **Contig**             **EC974**   **EC1515**   **Identity (%)**             
  ---------------------- ----------- ------------ ------------------ --------- --------
  Chromosome             1           941792       1                  941792    100.00
  Chromosome             941792      3045882      940823             3044907   99.99
  Chromosome             3045861     3047678      3046703            3044886   99.89
  Chromosome             3047657     5168339      3046682            5167364   99.99
  pEC974-1 & pEC1515-1   1           17197        1                  17187     99.91
  pEC974-1 & pEC1515-1   17205       17664        17720              18164     95.03
  pEC974-1 & pEC1515-1   17974       105321       18145              105492    99.99
  pEC974-2 & pEC1515-2   1           92404        1                  92352     99.94
  pEC974-3 & pEC1515-3   1           78518        1                  78518     100.00

###### 

High quality SNPs and small INDELs between the EC974 and EC1515 genomes.

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Contig**             **Strain 974**   **Strain 1515**   **Mutation type[^a^](#TN1){ref-type="table-fn"}**   **Gene product**              
  ---------------------- ---------------- ----------------- --------------------------------------------------- ------------------ ---------- ------------------------------------------------------
  **SNPs**                                                                                                                                    

  Chromosome             1378463          C                 1377490                                             G                  ns (A-P)   Putative transcriptional repressor

  Chromosome             1588773          A                 1587799                                             G                  ns (M-V)   Outer membrane protein G precursor

  Chromosome             1857685          C                 1856711                                             T                  s          Putative transport protein

  Chromosome             2230098          T                 2229124                                             G                  nc         --

  Chromosome             2414261          A                 2413286                                             T                  ns (Q-L)   Response regulator BaeR

  Chromosome             2514423          G                 2513448                                             C                  nc         --

  Chromosome             3073707          A                 3072732                                             T                  ns (D-E)   Primosomal protein I

  Chromosome             3260965          G                 3259990                                             A                  ns (S-F)   Lactaldehyde reductase

  Chromosome             4466967          G                 4465993                                             T                  ns (G-V)   ATP-dependent DNA helicase RecQ

  pEC974-1 & pEC1515-1   1392             T                 1392                                                A                  nc         --

  pEC974-1 & pEC1515-1   49297            T                 49468                                               A                  ns (W-R)   β-lactamase

  pEC974-1 & pEC1515-1   49349            T                 49520                                               C                  ns (V-A)   β-lactamase

  **INDELs**                                                                                                                                  

  Chromosome             1524239          T                 1523265                                             --                 fs         Hypothetical protein

  Chromosome             2352437          T                 2351462                                             --                 fs         Glycosyltransferase

  pEC974-1 & pEC1515-1   16847            C                 16842                                               --                 fs         Conjugative transfer pilus-tip adhesin protein, PilV

  pEC974-1 & pEC1515-1   17171            G                 17160                                               --                 nc         --

  pEC974-1 & pEC1515-1   17173            A                 17161                                               --                 nc         --

  pEC974-1 & pEC1515-1   17177            --                17166                                               T                  nc         --

  pEC974-1 & pEC1515-1   17178            --                17168                                               C                  nc         --

  pEC974-2 & pEC1515-2   36578-36629      CAGAAA\           36577                                               \-                 fs         Transposon Tn21 modulator
                                          TGCTCC\                                                                                             
                                          ACGTAC\                                                                                             
                                          TCGGCC\                                                                                             
                                          CCTTCC\                                                                                             
                                          GGCGTG\                                                                                             
                                          AAGGCG\                                                                                             
                                          GCATCG\                                                                                             
                                          AGCG                                                                                                
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

*ns, non-synonymous; s, synonymous; nc, non-coding region; fs, frame-shift*.

According to our annotation, the large deleted segments on chromosome contained two mobile element genes. The left boundary of the inversion on chromosome does not break any gene, but the right one broke a gene coding for phage tail fiber protein. The inverted segments contained two genes for phage tail fiber assembly. On the largest plasmid, the insertion did not break any gene and no gene was annotated in the inserted segment. The deletion broke a gene coding for Incl1 plasmid conjugative transfer pilus-tip adhesin protein, PilV.

We next examined the genes associated with repair systems in EC974 and EC1515 to determine whether EC1515 was a hypermutator. The results showed that the base excision repair system (uracil-DNA glycosylase, endonuclease III), nucleotide excision repair system (UvrABC), mismatch repair (MutSLH), and repair related genes (*recA, recF, radA*, and *radC*) were identical in EC974 and EC1515. However, RecQ, an ATP-dependent DNA helicase involved in DNA repair, showed an amino acid substitution in EC1515 (Table [5](#T5){ref-type="table"}).

The numbers of plasmid in isolates EC974 and EC1515 were verified by Kado-Liu\'s method (Figure [S3](#SM1){ref-type="supplementary-material"}). The results showed three plasmids with replicons IncI1, P0111, and IncFII were found in both isolates (Table [3](#T3){ref-type="table"}). Moreover, a high similarity of plasmid sequences between EC974 and EC1515 was observed (Table [4](#T4){ref-type="table"}). These results excluded the possibility of lateral acquisition of plasmids and indicated the evolution of plasmids within the host. Conjugation-related genes were identified in IncI1- and IncFII plasmids. P0111-type plasmids pEC974-2 and pEC1515-2, contained the antibiotic resistance genes *aadA2, tetA*, and *drfA12*, which confer resistance to aminoglycosides, tetracycline, and trimethoprim, respectively (Table [3](#T3){ref-type="table"}). IncFII-type plasmids pEC974-3 and pEC1515-3 contained antibiotic resistance genes *bla*~TEM−1~, *aadA1, aadA22, sul3*, and *inuF*. Interestingly, *aadA22, aac(3)-IId*, and *bla*~CMY−111~ were found in IncI1-plasmid pEC974-1, and *aadA22, aac(3)-IId*, and *bla*~CMY−4~ were identified in pEC1515-1 (Table [3](#T3){ref-type="table"}). *bla*~CMY−4~ was different from *bla*~CMY−111~ by W221R and V238A substitutions. Both *bla*~CMY~ genes were located downstream of an IS*Ecp1* (family, IS1380), an element commonly associated with *bla*~CMY~ genes (Seiffert et al., [@B34]).

Resistance gene transfer and plasmid analysis
---------------------------------------------

*bla*~CMY−111~ was first identified in *Serratia marcescens* strain A4Y201 (Boyd et al., [@B6]); however, the function of *bla*~CMY−111~ in conferring antibiotic resistance is still unclear. Transfer of antibiotic resistance phenotypes in pEC974-1 and pEC1515-1 was determined by conjugation tests, and the plasmid sizes present in parental isolates and transconjugants were verified by Kado and Liu\'s methods (Figure [S3](#SM1){ref-type="supplementary-material"}). We randomly selected 10 transconjugants derived from EC974 and EC1515, and the results revealed that all transconjugants contained two plasmids, in IncI1- and IncFII groups (Figure [S3](#SM1){ref-type="supplementary-material"}). Transconjugants harboring *bla*~CMY~-~4~ (EC1515-TCG) or *bla*~CMY~-~111~ (EC974-TCG) showed higher level resistance to AMP, AMC, CZ, CXM, CTX, CFM, and CAZ, but not TZP, FEP, or ETP (Table [6](#T6){ref-type="table"}). We further cloned *bla*~CMY~-~4~ and *bla*~CMY~-~111~ genes into pACYC177 to verify their resistance phenotypes. Compared to the DH5α cells, DH5α-*bla*~CMY~-~4~ and DH5α-*bla*~CMY~-~111~ were highly resistant to AMP, AMC, CZ, CXM, CTX, CFM, and CAZ (Table [6](#T6){ref-type="table"}). These results indicated that *bla*~CMY~-~4~ and *bla*~CMY~-~111~ showed similar antibiotic resistance characteristics.

###### 

Antibiotic susceptibility of the *E. coli* strains.

  **Strains**           **Antibiotic susceptibility (diameter, mm)**                                                                                                                                            
  --------------------- ---------------------------------------------- -------- -------- -------- -------- -------- -------- -------- ---------- -------- -------- -------- -------- -------- -------- -------- --------
  EC974                 R (6)                                          R (7)    I (18)   R (6)    R (6)    R (6)    R (6)    R (6)    S (25)     S (25)   S (23)   S (30)   S (18)   I (17)   S (25)   S (24)   R (6)
  EC1515                R (6)                                          R (6)    R (10)   R (6)    R (6)    R (6)    R (6)    R (6)    SDD (19)   S (26)   R (17)   S (29)   S (18)   I (17)   S (26)   S (26)   R (6)
  C600                  S (16)                                         S (23)   S (35)   S (31)   S (30)   S (36)   S (27)   S (42)   S (42)     S (36)   S (40)   S (42)   S (32)   S (35)   S (25)   S (26)   S (32)
  EC974-TCG             R (6)                                          R (7)    S (22)   R (6)    R (6)    R (14)   R (6)    R (17)   S (35)     S (32)   S (31)   S (39)   S (33)   S (36)   S (27)   S (28)   S (28)
  EC1515-TCG            R (6)                                          R (7)    S (26)   R (6)    R (6)    R (10)   R (6)    R (12)   S (35)     S (37)   S (35)   S (40)   S (36)   S (37)   S (28)   S (29)   S (29)
  DH5α                  S (20)                                         S (26)   S (36)   S (31)   S (30)   S (35)   S (30)   S (42)   S (40)     S (36)   S (45)   S (39)   S (32)   S (34)   S (27)   S (28)   S (37)
  DH5α-pACYC177         R (6)                                          S (19)   S (30)   S (29)   S (33)   S (40)   S (34)   S (48)   S (41)     S (43)   S (40)   S (44)   S (37)   S (40)   S (30)   S (33)   S (45)
  DH5α-*bla*~CMY−111~   R (6)                                          R (6)    S (26)   R (6)    R (6)    R (8)    R (6)    R (12)   S (35)     S (29)   S (29)   S (32)   S (31)   S (33)   S (27)   S (29)   S (35)
  DH5α-*bla*~CMY−4~     R (6)                                          R (6)    S (23)   R (6)    R (6)    R (6)    R (6)    R (10)   S (35)     S (30)   S (35)   S (34)   S (30)   S (33)   S (26)   S (28)   S (35)

*Antibiotic susceptibility tests were performed in duplicate*.

*AMP, Ampicillin; AMC, Amoxicillin; TZP, Piperacillin/Tazobactam; CZ, Cefazolin; CXM, Cefuroxime; CAZ, Ceftazidime; CFM, Cefixime; FEP, Cefepime, IPM, Imipenem; ETP, Ertapenem; MEM, Meropenem; LVX, Levofloxacin; CIP, Ciprofloxacin; GN, Gentamycin; AN, Amikacin; SXT, Cotrimoxazole*.

*S, sensitive; SDD, susceptible-dose dependent; I, intermediate resistance; R, resistant*.

Mechanisms associated with ertapenem resistance in EC1515
---------------------------------------------------------

To investigate the mechanisms contributing to ETP resistance in EC1515, the nucleotide sequences and protein levels of OmpA, OmpC, OmpF, and OmpR were analyzed. The western blot results showed that the expression of OmpA, OmpC, and OmpF was similar between EC974 and EC1515 (data not shown), and the results were similar to our previous report (Yan et al., [@B39]). Sequences of *ompA, ompC, ompF*, and *ompR* were identical between EC974 and EC1515. Moreover, the promoter region and sequence of the chromosome-borne, extended-spectrum AmpC (ESAC) β-lactamase were identical between EC974 and EC1515.

Discussion {#s4}
==========

This study characterized genome-wide and phenotypic changes that have occurred in the *E. coli* ST219 clone after nearly 4 months of chronic carriage and antibiotic treatments. Recurrent UTI is one of the most common bacterial infections in older women and children and poses a major clinical challenge worldwide (Guglietta, [@B13]). Tapiainen et al. showed that recurrent infection isolates were found to form biofilms effectively (Tapiainen et al., [@B36]). Moreover, the adhesiveness and invasiveness on the cells were significantly higher for *K. pneumoniae* recurrent strains than for initial colonized strains (Lin et al., [@B23]). Here, we showed that the patient with a recurrent UTI was infected by the same ST219 clone, retrievable as isolates EC974 and EC1515. Moreover, EC974 and EC1515 displayed different colony morphologies, with a rougher colony morphology of EC1515 compared to EC974 (Figure [S1](#SM1){ref-type="supplementary-material"}). These results indicate evolution of EC974 *in vivo*, with phenotype changes, during adaptation to the host and exposure to antibiotics.

One of the strategies that bacteria adopt to survive stress conditions is a change in morphology. Such changes were observed in bacteria on exposure to toxic organic compounds in *Pseudomonas putida* and *Enterobacter* sp. (Neumann et al., [@B27]). Temperature was reported to induce morphological changes in *E. coli* (Bennett et al., [@B5]) and *P. pseudoalcaigenes* (Shi and Xia, [@B35]). The sequence of antigen 43, an autotransporter in *E. coli* involved in cell aggregation, biofilm, and colony morphology (Kjaergaard et al., [@B20],[@B21]), was found to be identical between EC974 and EC1515. In addition, the metabolic pathways for glycolysis and gluconeogenesis determined by KEGG were the same between the two strains (data not shown). Chiang-Ni et al. reported that the hypermucoid variants of *Streptococcus pyogenes* showed a growth-defective phenotype in regular broth culture conditions and are significantly more susceptible to various DNA-damaging treatments when compared with the mucoid variant (Chiang-Ni et al., [@B7]). Therefore, whether EC1515 displays higher efficacy for cell colonization, biofilm formation, or stress tolerance compare to EC974, thus leading to recurrent UTI, is worth investigating.

Due to the lengthy antibiotic treatment regiments administered to many recurrent UTI patients, this cohort is at an elevated risk of developing multi-drug-resistant infections. Here, we showed that after CRO, CFM, and IMP treatments, EC1515, isolated from the patient with a recurrent UTI infection, was more resistant to TZP, FEP, CPO, and ETP, compared to EC974 (Table [2](#T2){ref-type="table"}). Comparative genomic results revealed no new resistance genes acquired by EC1515 during antibiotic treatments (Table [3](#T3){ref-type="table"}). We identified *bla*~CMY−111~ in *E. coli*, and demonstrated *bla*~CMY−4~ evolved from *bla*~CMY−111~ by W221R and V238A substitutions within the host. Moreover, *bla*~CMY−4~ showed similar antibiotic resistance patterns (Table [6](#T6){ref-type="table"}). Therefore, the acquired resistance genes did not cause resistance to TZP, FEP, CPO, and ETP in EC1515.

We noticed a cluster of small INDELs within the 16-18 kb region of the largest plasmid and the assembly qualities at many of those INDEL loci were low. The low assembly qualities were not the results of low read coverage. On the contrary, the coverage depth of the largest plasmid was about six times greater than the mean depth of the chromosome for both strains. This indicates multiple copies of the largest plasmids in the bacteria, consistent with the results shown in Figure [S3](#SM1){ref-type="supplementary-material"}. It is possible that there are slightly different versions of that plasmid, resulting in ambiguous assemblies at those small INDEL loci. We also found that the inserted segment on the largest plasmid of strain EC1515 was highly similar to a contig segment of EC974, but that contig was discarded due to its small length (2,061 bp) and low coverage (9.6 X) at the beginning. It is possible that the segment was acquired into the largest plasmid in the strain 1515. The small differences between the two genomes suggest that strain EC1515 really evolved from EC974.

Here, we revealed 12 SNPs and 8 INDELs (quality ≥ 30) in EC1515, compared with EC974, that arose during a 4-month persistent infection within host (Table [5](#T5){ref-type="table"} and Table [S1](#SM1){ref-type="supplementary-material"}). The mutation rate in EC1515 was higher, when compared with a previous report (1.1 per genome/year) (Reeves et al., [@B33]). Our results suggest that antibiotic exposure not only imposes a selective challenge to bacterial cells but also accelerates the rate of adaptation by selecting for advantageous mutations, consistent with a previous report (Long et al., [@B25]). Moreover, our comparative sequence results revealed a SNP of the RecQ protein (repair-related protein) in EC1515 (Table [5](#T5){ref-type="table"}). Yang et al. reported that the mutation of RecQ resulted in a mutator phenotype in *E. coli* cells (Yang et al., [@B40]). However, the mutation rate in EC974 and EC1515 remains to be determined.

ETP has become an important option for the treatment of *E. coli* infections. ETP-resistant *E. coli* strains may appear susceptible to IMP and MEP in routine susceptibility tests (Yan et al., [@B39]). Combinations of mutations in *envZ, ftsI, mrdA, acrB*, and *acrR* can cause high-level carbapenem resistance, independent of reduced *ompCF* expression in *E. coli* (Adler et al., [@B1]). However, all known genes involved in ETP resistance in *E. coli* were identical between EC974 and EC1515. We identified SNPs in two regulators (putative transcriptional repressor and BaeR) in EC1515 (Table [5](#T5){ref-type="table"}). However, whether the SNPs in EC1515 regulators lead to differential gene expression between EC974 and EC1515 is unclear. The development of next generation sequencing technologies, whole genome sequence and RNA-seq, has provided a novel means to study host-pathogen interaction and bacterial evolution within-host. Therefore, whether the gene expression patterns in EC1515 are different from that in EC974 and thus lead to ETP resistance remains to be clarified by RNA-seq. Moreover, the results raised the possibility that ETP resistance may be caused by a combination of several mutations. In summary, we first identified an IncI1-plasmid carrying *bla*~CMY−111~ in *E. coli* and observed its evolution to *bla*~CMY−4~ *in vivo*.
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